News
H1 2022: Temporary supply constraints slow down strong demand
H1 2022: Temporary supply constraints slow down strong demand
Orascom Development Holding AG: Closing of CHF 149 million transaction with Vail Resorts, Inc. by Andermatt Swiss Alps
Orascom Development Holding AG: Closing of CHF 149 million transaction with Vail Resorts, Inc. by Andermatt Swiss Alps
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Finalization of Vifor Pharma acquisition
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Meyer Burger adjusts expected production volumes for 2022 and 2023
Meyer Burger adjusts expected production volumes for 2022 and 2023
Implenia wins further large, complex real estate projects in western Switzerland
Implenia wins further large, complex real estate projects in western Switzerland
Interroll significantly increases sales in a difficult market environment
Interroll significantly increases sales in a difficult market environment
Invitation Half-Year 2022 Results Media and Investor Conference Call and Webcast
Invitation Half-Year 2022 Results Media and Investor Conference Call and Webcast
Double-digit sales growth in local currencies in all regions – negative currency effects on sales and earnings – results also hit by significant rise in cost of raw materials
Double-digit sales growth in local currencies in all regions – negative currency effects on sales and earnings – results also hit by significant rise in cost of raw materials
INFICON Achieves Double-digit Growth in Q2 2022 Based on Good Order Situation and Growing Production Capacities
INFICON Achieves Double-digit Growth in Q2 2022 Based on Good Order Situation and Growing Production Capacities
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Bellevue reports a market related decline in net profit for the first half to CHF 14.3 mn – client base stable thanks to acknowledged investment expertise
Bellevue reports a market related decline in net profit for the first half to CHF 14.3 mn – client base stable thanks to acknowledged investment expertise
LEM announces results for Q1 2022/23: solid sales performance, increased order book and robust profitability
LEM announces results for Q1 2022/23: solid sales performance, increased order book and robust profitability
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
CALIDA Holding AG: Founding family Kellenberger seeks succession arrangement as CALIDA GROUP’s anchor shareholder
CALIDA Holding AG: Founding family Kellenberger seeks succession arrangement as CALIDA GROUP’s anchor shareholder
Comet Group on plan for full year guidance, successfully managed supply chain in the first half of 2022
Comet Group on plan for full year guidance, successfully managed supply chain in the first half of 2022
Metall Zug AG: Clearances granted for closing of the combination between Schleuniger and Komax
Metall Zug AG: Clearances granted for closing of the combination between Schleuniger and Komax
Competition authorities grant clearance for combination of Komax and Schleuniger
Competition authorities grant clearance for combination of Komax and Schleuniger